Viewing nowSita Down Tablets 25 mg (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 28.34mg
Tablet · Prescription medication
HyunDae Pharm Co., Ltd.

MFDS item code 202102464 · Approved 2021.03.19 · Insurance code 642004960
Improves blood glucose control in type 2 diabetes mellitus
This medication is used to improve blood sugar control in patients with type 2 diabetes. In initial therapy, it can be administered alone, and if blood sugar control is difficult, it is used in combination with Metformin. Additionally, it can be used together with other diabetes medications such as sulfonylureas, thiazolidinediones, and insulin when sufficient blood sugar control is not achievable alone or in combination therapy. This aids in more effective blood sugar control along with dietary and exercise regimens. Overall, this medication is utilized to enhance blood sugar control in patients with diabetes across various treatment stages.
This medication is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medication and periodically thereafter. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered without regard to the timing of dialysis.
This medication may cause severe allergic reactions after administration; therefore, if symptoms like skin rash or difficulty breathing occur, use should be discontinued immediately, and a physician should be consulted. This medication has the potential to cause a serious pancreatic disease called pancreatitis, so if symptoms like abdominal pain or vomiting occur, healthcare personnel should be notified immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication, and those allergic to this drug or its ingredients should also avoid administration. Patients with impaired kidney function may have delayed excretion of this medication, so dosage adjustments or careful use may be necessary. While using this medication, symptoms such as headaches, cold symptoms, rhinitis, indigestion, and diarrhea may occur; if symptoms persist, it is advised to consult a physician. When taken together with insulin or sulfonylureas, the risk of hypoglycemia may increase; therefore, blood sugar levels should be checked regularly, and dosage adjustments may be needed if necessary. Severe joint pain or bullous pemphigoid may occur, so if these symptoms appear, medication should be discontinued immediately, and a specialist's care should be sought. Pregnant or breastfeeding women are advised to avoid the use of this medication, and its safety has not been established in children and adolescents under 18 years of age. For the elderly, it is important to adjust the dosage and periodically monitor kidney function since kidney function may decline. In cases of overdose, general emergency measures should be taken, and hemodialysis may be performed if necessary to remove the drug. This medication has confirmed cardiovascular safety and does not increase the risk of heart disease, but regular check-ups are recommended during administration. While the potential for drug interactions is low, it is advisable to inform healthcare personnel of any medications being taken and to receive appropriate monitoring.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory infection, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia accompanied by severity and disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, elevated liver enzymes, acute renal failure, rash, urticaria, cutaneous vasculitis, rhabdomyolysis, dyspepsia, dizziness, increased ALT, increased AST, elevated blood triglycerides, gastritis, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or humidity, and it is best to keep it at room temperature between 1 to 30 degrees Celsius. Proper storage can help maintain the drug's efficacy over time.
Bright yellow-orange round film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 28.34mg
Tablet · Prescription medication
HyunDae Pharm Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.